Cardiovascular pharmacology

Jump to navigation Jump to search

WikiDoc Resources for Cardiovascular pharmacology

Articles

Most recent articles on Cardiovascular pharmacology

Most cited articles on Cardiovascular pharmacology

Review articles on Cardiovascular pharmacology

Articles on Cardiovascular pharmacology in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cardiovascular pharmacology

Images of Cardiovascular pharmacology

Photos of Cardiovascular pharmacology

Podcasts & MP3s on Cardiovascular pharmacology

Videos on Cardiovascular pharmacology

Evidence Based Medicine

Cochrane Collaboration on Cardiovascular pharmacology

Bandolier on Cardiovascular pharmacology

TRIP on Cardiovascular pharmacology

Clinical Trials

Ongoing Trials on Cardiovascular pharmacology at Clinical Trials.gov

Trial results on Cardiovascular pharmacology

Clinical Trials on Cardiovascular pharmacology at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cardiovascular pharmacology

NICE Guidance on Cardiovascular pharmacology

NHS PRODIGY Guidance

FDA on Cardiovascular pharmacology

CDC on Cardiovascular pharmacology

Books

Books on Cardiovascular pharmacology

News

Cardiovascular pharmacology in the news

Be alerted to news on Cardiovascular pharmacology

News trends on Cardiovascular pharmacology

Commentary

Blogs on Cardiovascular pharmacology

Definitions

Definitions of Cardiovascular pharmacology

Patient Resources / Community

Patient resources on Cardiovascular pharmacology

Discussion groups on Cardiovascular pharmacology

Patient Handouts on Cardiovascular pharmacology

Directions to Hospitals Treating Cardiovascular pharmacology

Risk calculators and risk factors for Cardiovascular pharmacology

Healthcare Provider Resources

Symptoms of Cardiovascular pharmacology

Causes & Risk Factors for Cardiovascular pharmacology

Diagnostic studies for Cardiovascular pharmacology

Treatment of Cardiovascular pharmacology

Continuing Medical Education (CME)

CME Programs on Cardiovascular pharmacology

International

Cardiovascular pharmacology en Espanol

Cardiovascular pharmacology en Francais

Business

Cardiovascular pharmacology in the Marketplace

Patents on Cardiovascular pharmacology

Experimental / Informatics

List of terms related to Cardiovascular pharmacology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Scope

  • 5% of questions on the cardiovascular boards pertain to cardiovascular pharmacology.

Pharmacokinetics

Pharmacokinetics is the effect of the body on the drug.

Potency vs Efficacy

  • Potency is a meaningless measure of the effect of drug on a per mg basis. Says nothing aobut the clinical effectiveness of the drug.
  • Efficacy is the clinical effectiveness of drug.
  • A new more potent medicine will achieve the desired effect at a lower dose. It may not be more effective.

Drug Distribution

Hydrophilic Drugs

  • These drugs stay in the intravascular space
  • Cleared by kidney
  • Don't cross the lipid blood brain barrier
  • Examples include: Atenolol, nadolol, sotalol
  • Muscle is high in water content.
  • Women have less muscle mass thereby lowering the volume of distribution of hydrophilic drugs.
  • Older patients have less muscle mass thereby lowering the volume of distribution of hydrophilic drugs.
  • Elderly women have less total body water thereby lowering the volume of distribution of hydrophilic drugs.
  • Water soluble (hydrophilic) drugs are associated with a higher drug effect in patients with a lower volume of distribution like elderly women (e.g. alcohool in a woman).
  • Impaired kidney function affects hydrophilic drugs as impaired kidney function affects the volume of distribution.
  • Avoid these drugs in renal insufficiency
  • Hydrophiic drugs do not diffuse into brain. This is very important in the selection of beta blockers
  • Hydrophilic drugs that don't cross the blood brain barrier:
  • Atenolol. This would be a good drug for rate control in atrial fibrillation in an older patient with depression.
  • Nadolol
  • Sotalol
Lipophilic drugs do cross the blood brain barrier (don't give these drugs to a depressed patient):

Lipophilic Drugs

Intestinal Metabolism

Grapefruit Juice

  • Grapefruit juice blocks the intestinal cytochrome Cyp3A4 metabolism but not that in the liver.
  • May drugs that undergo major intestinal CYP3A metabolism
  • Variable effect because patients are so variable in the expression of CYP3A
  • One glass of grapefruit juice may irreversibly inhibits CYP3A system up to 3 days
  • Drugs affected by grapefruit juice:
  • Drugs that are not affected:

Hepatic Metabolism

  • Drugs can either inhibit or induce hepatic metabolism.

Inducers

The following drugs induce hepatic metabolism:

Inhibitors

Pharmacodynamics

Pharmacodynamics relate to the effect of the drug on the body (in essence the obverse of pharmacokinetics).

Digoxin

Teratogenicity

Drugs to be Avoided in Pregnancy

Drugs that are More Acceptable to use in Pregnancy

Drugs in Lactation

Drug Overdose Management

Beta Blocker

Calcium Channel Blocker

Caffeine

Cardiotoxicity of Non-Cardiovascular Drugs

Type I Irreversible Cardiotoxcity (e.g.CHF with anthracylines)

  • Cardiotoxicity is related to the cumulative dose: 400 to 500 mg / m2 is teh threshold where toxicity begins
  • This level of exposure occurs at about one year
  • There is a progressive asymptomatic progression in left ventricular dysfunction
  • Progression of disease may persist after discontinuation of anthracycline therapy
  • Risk factors include age extremes: younger and old age
  • Pathphysiology is increased apoptosis and accelerated myocyte death
  • Goal: minimize further exxposure, treat CHF symptoms, avoid re-exposure and minimizes re-exposure.

Type II Reversible Cardiotoxicity

  • With these agents re-challenge may be safe
  • Examples:

Drug Interactions

PDE 5 Inhibitors

  • Nitrates cause hypotension when administered with PDE5 inhibitors such as viagra
  • This is due to excessive cyclic GMP induced vasodilation

ACE Inhibitors, Spironolactones and Postassium

  • Dangerous combination

St. John's Wart

Supplements that Increase Bleeding Effect

  • Ginger

Adverse Drug Reactions

  • 4th leading cause of death
  • One third are preventable, but often we don't know what the patient is taking
  • Elderly and youngerly are at increased risk
  • Elderly are at risk because of reduced muscle mass, water soluble drug concentration increased, decreased renal function, cognitive decline and mix up of med doses, non-compliance, co-morbidities
  • Polypharmacy: If a patient is administered over 5 drugs, there is a higher risk of drug interactions. Elderly are often on over 10 drugs

Pharmacogenomics

  • Role of inheritance in variation in drug response
  • Metabolism, absorption, interaction of drug with the target may also be affected by genetics
  • Genetics may influence induction and (breakdown) of drugs, increase or reduce activity of drug

Cyp2D6

  • Poor metabolizers: observed in 10% of northern europeans. Metoprolol is not broken down and these patients are susceptible to overdosing of beta-blcokers but codeine does not work in these patients.
  • Ultrametabolizers: East africans can be ultrametabolizers: lopressor does not work, codeine can be toxic

Clopidogrel

  • Pro-drug
  • Absorption variable
  • 15% of ingested drug is converted ot active metabolite in two step process in liver
  • CYP2c19 very important in metabolizing the drug to the active metabolite
  • The *2 and *3 polymorphisms are inactive, drug not converted to active meatbolite, inadequate activity. Increase adverse events, stent thrombosis.
  • Routine testing not recommended
  • If *2 or *3 allele present, then alternate therapy recommended. Pateint with stent thrombosis on clopidogrel may undergo genetic testing and switch to a newer antiplatelet agent.

Warfarin

  • INR is related to efficacy and bleeding
  • Order of magnitude different doses of warfarin due to genetic difference
  • Half of variability is due to geneitc variability
  • CYP2C: responsible for metabolism (pharmacokineteics). There are slow and fast metabolizers
  • VKORc1: affects target of effect of warfarin (pharmacodynamics)
  • Not clear if testing is cost-effective

References